Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R131-2 (interferon alfa-2b)
- Development stage
- Phase 1
- Lead developer
- Zenith Technology Corp
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Vaginal
01
Overview
R131-2 is a specialized intravaginal soft gel capsule formulation of recombinant human interferon alfa-2b (rhIFN alfa-2b) developed by Zenith Technology Corporation Limited. It is designed for the localized treatment of human papillomavirus (HPV)-related conditions, including cervical intraepithelial neoplasia (CIN) and condyloma acuminatum (genital warts). As a type I interferon, it binds to the IFNAR1 and IFNAR2 receptor complex, triggering the JAK-STAT signaling pathway to induce an antiviral state in target cells, inhibit viral replication, and enhance the host's immune response against virally infected or neoplastic cells. The soft gel capsule formulation is intended to provide improved stability and patient compliance compared to traditional vaginal suppositories or creams.
- Other names
- recombinant human interferon alpha-2brhIFN alpha-2binterferon alpha-2b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IRF9 (Interferon regulatory factor 9)JAK1 (Janus kinase 1)STAT (STAT family)TYK2 (Tyrosine kinase 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on R131-2 (interferon alfa-2b).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R131-2 (interferon alfa-2b).